Ars Technica Follow OTC nasal spray seemed to cut COVID infections by 67% in mid-sized trial The Phase 2 trial is not definitive, but it comes as vaccine access is severely restricted. https://arstechnica.com/health/2025/09/otc-nasal-spray-seemed-to-cut-covid-infections-by-67-in-mid-sized-trial/ arstechnica.com
